Dr. Robert Toto is the Mary M. Conroy Professor of Kidney Disease and Director of Clinical Nephrology and Patient-Oriented Research in Nephrology at The University of Texas Southwestern Medical Center, Dallas, Texas. He received his MD degree from the University of Illinois in Chicago in 1977 and did his Internal Medicine training at the University of Michigan in Ann Arbor and Baylor College of Medicine in Houston, Texas. He completed his nephrology training at University of Texas Southwestern Medical Center in Dallas in 1983 and joined the full-time faculty immediately thereafter.
Dr. Toto is nationally and internationally known for clinical research and teaching. He has awarded numerous teaching awards from Medical Students and Residents at UT Southwestern Medical Center and is a regular speaker at National and International Nephrology meetings on a variety of topics in renal disease. He has served on program committees for the American Society of Nephrology, the International Congress of Nephrology and the National Kidney Foundation and is actively involved with training and research policy development at the National level through the American Society of Nephrology and National Institutes of Health.
Dr. Toto has authored more than 100 original articles and textbook chapters related to diagnosis and management of hypertension and kidney diseases. His published work includes pathophysiology of hypertensive and diabetic renal diseases, dyslipidemia in chronic kidney disease, novel risk factors for diabetic nephropathy, anemia in patients with chronic kidney disease and dialysis-related morbidity and mortality and other complications of kidney disease. In addition, he has served on the editorial boards of Kidney International, Journal of American Society of Nephrology, the American Journal of Kidney Disease and Nephrology, American Journal of Nephrology, Nephrology Dialysis and Transplantation and Current Opinion in Nephrology and Hypertension.
Dr. Toto’s research interests include detection, prevention and treatment of progressive kidney diseases including diabetes and hypertension. He has been involved with major federally supported clinical trials in nephrology including the African-American Study of Kidney Disease (AASK trial), the HEMO study, the Reduction in Endpoints in NIDDM with the Angiotensin Antagonist Losartan and the Irbesartan in Diabetic Nephropathy Trial. |